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Abstract
Arsenite (As(III)) is widely distributed in nature and can be
found in water, food, and air. There is significant evidence
that exposure to As(III) is associated with human cancers
originated from liver, lung, skin, bladder, kidney, and pros-
tate. Hypoxia plays a role in tumor growth and aggressive-
ness; adaptation to it is, at least to a large extent, mediated
by hypoxia-inducible factor-1α (HIF-1α). In the current
study, we investigated As(III) effects on HIF-1α under
normoxia and hypoxia in the hepatoma cell line HepG2.
We found that As(III) increased HIF-1α protein levels un-
der normoxia while the hypoxia-mediated induction of
HIF1α was reduced. Thereby, the As(III) effects on HIF-
1α were dependent on both, transcriptional regulation via
the transcription factor Nrf2 mediated by NOX4, PI3K/
Akt, and ERK1/2 as well as by modulation of HIF-1α
protein stability. In line, the different effects of As(III)
via participation of HIF-1α and Nrf2 were also seen in tube
formation assays with endothelial cells where knockdown
of Nrf2 and HIF-1α abolished As(III) effects. Overall, the
present study shows that As(III) is a potent inducer of HIF-
1α under normoxia but not under hypoxia which may
explain, in part, i ts carcinogenic as well as anti-
carcinogenic actions.
Key message
& As(III) increased HIF-1α under normoxia but reduced its
hypoxia-dependent induction.
& The As(III) effects on HIF-1α were dependent on ROS,
NOX4, PI3K/Akt, and ERK1/2.
& TheAs(III) effects under normoxia involved transcription-
al regulation via Nrf2.
& Knockdown of Nrf2 and HIF-1α abolished As(III) effects
in tube formation assays.
& The data may partially explain As(III)’s carcinogenic and
anti-carcinogenic actions.
Keywords Hypoxia-inducible factor 1 (HIF-1α) . Arsenite
As(III) . Mitogen-activated protein kinase (MAPK) . Reactive
oxygen species (ROS) . NADPH enzyme oxidase 4 (NOX4)
Introduction
Several regions in Argentina, Canada, India, Japan, China,
Taiwan, Mexico, Chile, and the USA are characterized by
the presence of inorganic arsenic as natural contaminant in
drinking water. This implies that more than 100 million per-
sons are chronically exposed to inorganic arsenic at levels
higher than the maximum contaminant level of 0.13 μmol/l
set by the WHO [1].
It is long known that chronic arsenic inhalation or in-
gestion is toxic and causes a number of health problems.
Although the clinical manifestations of arsenic toxicity
vary widely between persons and populations, chronic ex-
posure to arsenic is, if not causing death, associated with a
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greater risk of ischemic heart disease [2], neurologic con-
sequences [3] in adults and children [4] as well as with the
appearance of cancer [5] in the lung, skin, kidney, bladder,
and liver [6].
Solid tumors are characterized by the occurrence of
areas with limited oxygen supply and it was shown that
cells present in the hypoxic areas contain high levels of
the hypoxia-inducible factor-1 alpha protein (HIF-1α) (for
review, see [7]). The HIF-1α protein forms, together with
its heterodimeric partner HIF-1β or ARNT, the proper
transcription factor hypoxia-inducible factor-1 (HIF-1)
which has been found to be critical for the regulation of
more than 100 genes in response to hypoxia. A prerequi-
site for the formation of the HIF-1 heterodimer is the
hypoxia-dependent stabilization of the HIF-1α subunit
and the recruitment of coactivators. This is primarily
achieved at the post-translational level by hydroxylation
events occurring at the N-terminal (N-TAD) and C-
terminal (C-TAD) transactivation domain of HIF-1α
[7–9]. Further, phosphorylation events [10–12] and mech-
anisms leading to enhanced HIF-1α gene transcription
[13] also contribute to an increase in HIF-1α protein
levels. In addition to hypoxia, HIF-1α is also responsive
to a variety of non-hypoxic stimuli among them transition
metals such as CoCl2, chromium, or arsenite (for review,
see [14, 15]).
Although arsenite seems to exert some of its effects
through direct interaction of the trivalent arsenite anion
(AsO3
3–) with the thiol groups of vicinal cysteines in
target proteins [16, 17], the underlying mechanisms by
which arsenic contributes to HIF-1α activation and car-
cinogenesis are rather controversial [18–20] and thus
remain largely unknown. In particular, the effects of ar-
senite on the regulation of HIF-1α under tumor-
promoting conditions like hypoxia have never been ex-
plored. In order to gain a better understanding about the
mechanisms and actions involved when cells are ex-
posed to arsenite, we focused in the current study on
the impact of arsenite on HIF-1α regulation under
normoxia and hypoxia.
We found that arsenite induced the levels of HIF-1α
under normoxia via a transcriptional mechanism involving
NADPH oxidase-generated reactive oxygen species
(ROS), the PI3K/Akt and ERK1/2 pathway, and the
redox-dependent transcription factor Nrf2. Moreover, ar-
senite was able to induce DNA synthesis and angiogene-
sis in a Nrf2- and HIF-1α-dependent manner. By contrast,
arsenite reduced the hypoxia-dependent upregulation of
HIF-1α, though increasing its stability. Together, the cur-
rent findings indicate that arsenite may act as a powerful
modulator of the HIF system with different effects under
normoxia and hypoxia which may explain, in part, its
ambivalent role in cancer and its potential therapeutic use.
Materials and methods
All biochemicals and enzymes were of analytical grade and
purchased from commercial suppliers. Sodium arsenite
(As(III)), actinomycin D (ActD), and cycloheximide (CHX)
were purchased from Sigma. The specific inhibitors for the
mitogen-activated protein kinase (MEK) U0126 and
PD98059, the phosphatidylinositol 3-kinase (PI3K) inhibitor
LY294002, Jun N-terminal kinase (JNK) inhibitor SP600125,
and the p38 protein kinase inhibitor SB202190 were pur-
chased from Enzo, Roche Diagnostics GmbH (Mannheim).
Cell culture and cell treatment
Human hepatoma HepG2 cells were cultured in a normoxic
atmosphere at 16%O2, 79%N2, and 5%CO2 (by volume) in
Earle’s minimal essential medium supplemented with 10 %
fetal calf serum (FCS) for 24 h. At 24 h, the medium was
changed and the culture was continued under normoxic con-
ditions at 16%O2 or hypoxic conditions at 5 %O2 (with 90%
N2 and 5 % CO2 [by volume]).
Human microvascular endothelial cells (HMEC-1) were
cultured under the same atmospheres in MCDB131 medium
(Gibco) supplemented with 10 % FCS. Nrf2 knockdown
mouse embryonic fibroblasts were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) with 10 % fetal calf se-
rum and were a kind gift from S. Immenschuh.
For treatment of cells with As(III), cells were cultured in
60 mm diameter dishes and grown overnight. Thereafter,
As(III) was added to the media, and cells were further incu-
bated for the time periods indicated. None of the used As(III)
concentrations exerted unspecific cell damage or toxicity as
assessed by LDH leakage (data not shown). Pre-treatment of
cells with kinase inhibitors, ActD, and CHX was performed
for 30 min, respectively, prior to the addition of As(III).
Plasmid constructs
The reporter constructs for pGL3-EPO-HRE [21], p(ARE)-
p44-Luc [22], as well as siSTRIKE ™ U6 shRNA Nrf2,
siSTRIKE ™ U6 shRNA HIF-1α plasmids, siSTRIKE ™
U6 shNOX4 were described previously [23, 24].
RNA preparation and Northern blot analysis
The isolation of total RNA and Northern blot analysis were
performed as described previously [21]. Digoxigenin-labeled
antisense RNAs hybridization probes were generated by in
vitro transcription from pBS-Actin by using T7 polymerase
or from pCRII-HIF-1α and pBS-HO-1 by using T7 polymer-
ase. Blots were quantified with a video densitometer (Biotech
Fischer, Reiskirchen, Germany).
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Western blot analysis
Western blot analysis was carried out as described previ-
ously [21]. In brief, 100 μg of protein from medium or
total lysates from HepG2 cells was subjected to Western
blotting with monoclonal antibodies against PAI-1 (1:100;
American Diagnostics, Pfungstadt, Germany), HIF-1α
(1:1000; BD Biosciences, Heidelberg, Germany), phospho
p42/p44 MAPK (1:1000), phospho p38 MAPK (1:1000),
phospho Akt-T308 (1:1000) and phospho c-Jun-Ser63-
Ser73 (1:1000) (Cell Signaling) or rabbit polyclonal anti-
bodies against HO-1 (1:1000; Cell Signaling, Biomol,
Hamburg), Golgi membrane (58-kD cis-Golgi protein
formiminotransferase cyclodeaminase) (1:10,000;
Biosciences, Goettingen, Germany), or α-tubulin (1:10,
000; Sigma). The enhanced chemiluminescence (ECL)
system was used for detection (Amersham Biosciences).
Cell transfection and luciferase assay
About 4 × 105 HepG2 cells per 60 mm diameter dish were
transfected as described previously [11, 22]. In brief, cells
were transfected with 2 μg pGL3-EPO-HRE or p(ARE)-
p44-Luc, together with 0.25 μg of a Renilla luciferase expres-
sion construct (pRLSV40) (Promega, Heidelberg, Germany)
to control transfection efficiency. The detection of luciferase
activity was performed with a luciferase assay kit (Berthold,
Pforzheim, Germany).
For knockdown experiments, cells were transfected with
10 μg of the respective psiSTRIKE shRNA plasmids over-
night. The next day, the medium was changed and cells were
treated as described above.
Protein half-life
Protein half-life studies were performed in HepG2 cells
treated with 50 μM As(III) under normoxia and hypoxia
for 4 h. After 4 h, cycloheximide (100 μg/ml) was added to
the medium for different times and cells were further cul-
tured under normoxia and hypoxia. After harvesting the
cells, endogenous HIF-1α protein levels were measured
by immunoblot analysis.
Measurement of ROS
Measuring ROS was performed by using the non-fluorescent
dye dichlorodihydrofluorescein diacetate (H2DCFDA).
Fluorescence measurements were performed in six-well plates
(10,000 cells/well). The cells were treated with 50 μMAs(III)
and after 4 h the cells were washed with 1× PBS and 10 μM
H2DCFDA was added for 20 min at 37 °C in dark. DCF
fluorescence in each well was measured with a Fluoroscan
fluorescence plate reader at 37 °C at an excitation wavelength
of 488 nm and an emission wavelength of 538 nm. In addi-
tion, ROS measurements were performed by electron para-
magnet ic resonance (EPR) using the spin probe
1-hydroxymethoxycarbonyl-2,2,5,5-tetramethylpyrrolidine
hydrochloride (CMH, Noxygen, Elzach, Germany).
Briefly, cells were treated with As(III) in the presence or
absence of hypoxia (5 % O2) for 4 h. Cells were washed
once in 1× PBS, harvested in Krebs-Hepes buffer and sup-
plemented with 5 µM diethyldithiocarbamate, 25 µM
desferrioxamine, and 100 µM CMH under normoxic or
hypoxic conditions. Cell suspensions were placed in air-
tight glass capillaries and spectra were recorded in an
EPR spectrometer with temperature-controlled resonator
(e-scan, Noxygen). EPR settings for CMH spin label were
as follows: center field 3455 G, sweep width 10 G, frequen-
cy 9.7690 GHz, microwave power 23.89 mW, and modula-
tion amplitude 2.93 G. Spectra were recorded over 10 min.
BrdU cell proliferation and colony formation assay
HepG2 cells transfected with plasmids expressing control
scrambled shRNA or shRNA against HIF-1α or Nrf2 were
cultured with or without As(III) in 96-well plates for 4 h.
The bromodesoxyuridine (BrdU) assay (Calbiochem) was
performed according to the manufacturer’s instructions and
the absorbance was measured at dual wavelengths of 450
and 540 nm.
Colony formation was assessed in a Hep3B monolayer
assay by seeding cells at different densities (500–3000 cells/
well in steps of 500) in six-well plates and growing them for
4 days. Afterwards, cells were fixed and stained with crystal
violet counted and quantified.
In vitro matrigel angiogenesis assay
HMEC-1 cells were transfected with expression vectors for
shHIF-1α, shNrf2, or with the respective control vectors.
Cells were seeded at a density of 50,000 cells/well on a 96-
well plate mounted with growth factor reduced Matrigel (BD
Biosciences). The cells were allowed to settle for 2 h in
normoxia and were then cultured where indicated in the pres-
ence of As(III). After incubation, the cells were stained with
the fluorescent dye Calcein AM (Mobitec, Germany). The
formation of capillary-like structures was assessed by light
microscopy and quantified using Image J software (Wright
Cell Imaging Facility, Toronto, Canada).
Statistical analysis
Densitometry data were plotted as fold induction of relative
density units, with the zero value absorbance in each figure set
arbitrarily to 1 or 100 %. Statistical comparisons of absor-
bance differences were performed by the Mann-Whitney test
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(Statview 4.5, Abacus Concepts, Berkeley, CA), and p values
p ≤ 0.05 were considered significant. Values presented are
means ± SEM. Results were compared by ANOVA for repeat-
ed Luc measurements followed by the Newman-Keuls test. A
probability level p ≤ 0.05 was accepted as significant.
Results
Arsenite induces HIF-1α protein levels under normoxia
but reduces the effect of hypoxia
To examine the effect of As(III) on HIF-1α protein levels
in HepG2 cells, different concentrations of As(III) were
first applied to the cells for 4 h under normoxia and
hypoxia. The western blot analyses revealed that treatment
of cells with As(III) at concentrations of 10, 50, and
100 μM induced HIF-1α under normoxia (Fig. 1a, c); a
higher concentration of 300 μM As(III) did not exert an
effect on HIF-1α under normoxia (Fig. 1a, c).
Interestingly, the inducing effect of As(III) on HIF-1α
was lost when the As(III) treatment was performed under
hypoxia. While hypoxia alone exerted the strongest induc-
tion on HIF-1α (about 4-fold), co-treatment with 10, 50,
100, and also 300 μM As(III) reduced the hypoxia-
dependent induction of HIF-1α by about 20, 30, 50, and
100 %, respectively (Fig. 1a, c).
In addition, we determined a time course of the HIF-1α
response towards As(III) under normoxia and hypoxia. The
western blot analyses showed that As(III) slightly induced
HIF-1α protein levels already after 2 h under normoxia.
The induction increased and became maximal after 4 h;
thereafter HIF-1α levels did not increase further. In addi-
tion, the results show that the hypoxia-dependent HIF-1α
protein induction starts after 2 h; treatment with As(III) for
2 h and longer inhibited the hypoxia-dependent induction
of HIF-1α (Fig. 1b, c). Together, these data indicate that
treatment of cells with As(III) induced HIF-1α protein
levels under normoxia but reduced the hypoxia-dependent
HIF-1α induction.
Arsenite regulates HIF-1α at the transcriptional level
To gain insight into the mechanisms involved, we asked
whether As(III) regulates HIF-1α via transcriptional mecha-
nisms. Initial experiments with the transcription inhibitor
actinomycin D supported the notion that As(III) affects
HIF-1α transcription under normoxia and hypoxia (data
not shown). To further specify whether or not As(III) is able
to regulate HIF-1α expression at the mRNA level, Northern
blot analyses were performed. Time course experiments in-
dicated that As(III) induced HIF-1α mRNA levels by about
4-fold within 4 h of treatment under normoxia. However,
As(III) reduced HIF-1α mRNA levels by about 50 % under
hypoxia (Fig. 2a, b). Together, these data provide the first
evidence that As(III) is able to regulate HIF-1α at the tran-
scriptional level.
Fig. 1 Concentration- and time-dependent modulation of HIF-1α
protein levels by As(III) under normoxia and hypoxia. Cells were
cultured under normoxia (16 % O2) for 24 h. After 24 h, the medium
was changed and cells were further cultured under normoxia and hypoxia
(5 % O2) and treated either with: a different concentrations of As(III) for
4 h; b 50 μM As(III) for the indicated time points. The HIF-1α levels in
the absence of As(III) or in controls at 0 h were set to 1. Values represent
mean ± SEM of at least three independent experiments. Single asterisk,
significant difference control under normoxia vs. As(III); double
asterisks, significant difference control under hypoxia vs. As(III). c
Representative Western blot with 50 μM As(III) at 4 h. One hundred
micrograms of total protein was subjected to Western blot analysis with
an antibody against HIF-1α or Golgi membrane (GM). Autoradiographic
signals were visualized by chemiluminescence and quantified by video
densitometry
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Arsenite induces HIF-1α synthesis under normoxia
and prolongs its half-life under hypoxia
To further analyze the mechanisms by which As(III) regu-
lates HIF-1α levels, we next examined whether ongoing
protein synthesis or post-translational effects are involved.
To do this, we first used cycloheximide (CHX) as transla-
tion inhibitor. Like in the previous experiments, As(III)
induced HIF-1α strongly under normoxia but reduced the
hypoxia-dependent upregulation. When CHX was used, it
completely abolished the induction of HIF-1α by As(III)
under normoxia but also the response towards hypoxia or
combined treatment (Fig. 3a, b).
Since the above data indicated the involvement of pro-
tein synthesis in the regulation of HIF-1α by As(III), we
next asked whether this involves the rapamycin-sensitive
mTORC1 complex. The mTORC1 activates translation via
phosphorylation of p70-S6 Kinase-1 and the eukaryotic
initiation factor 4E binding protein 1 (4E-BP1) which con-
verge at the translation initiation complex at the 5′ end of
the respective mRNA.
To test the participation of mTORC1 in the As(III)-medi-
ated effects on HIF-1α, we used rapamycin as mTORC1 in-
hibitor. As before, treatment with As(III) under normoxia re-
sulted in a strong upregulation of HIF-1α. Rapamycin re-
duced the As(III)-dependent HIF-1α induction by about
50 % under normoxia but not under hypoxia (Fig. 3c, d).
These data support the notion that HIF-1α induction by
As(III) under normoxia involves mTORC1-regulated protein
synthesis; however, they do not exclude that As(III) may af-
fect HIF-1α protein stability under hypoxia. Therefore, we
also investigated whether As(III) has an effect on HIF-1α
protein stability. The half-life measurements indicated that
the HIF-1α half-life was about 20 min in As(III)-treated
normoxic cells (Fig. 4a). As mentioned above, As(III) was
found to reduce HIF-1α protein induction under hypoxia;
however, the half-life measurements showed that the HIF-1α
half-life after treatment with As(III) is prolonged in compari-
son to cells incubated only under hypoxia (Fig. 4c). Together,
these data indicate that under normoxic conditions As(III)
contributes to HIF-1α regulation primarily via induction of
transcription and translation whereas under hypoxia As(III)
is able to stabilize HIF-1α.
As(III) induces HIF-1α and the HIF-target genes PAI-1
and HO-1 via Nrf2
In a next step, we investigated the effect of As(III) on HIF
transcriptional activity and the HIF-1α target genes plasmin-
ogen activator inhibitor-1 (PAI-1) and heme oxygenase (HO-
1). The results demonstrate that hypoxia, as shown earlier
[25], induced PAI-1 expression by about 2.5-fold. As(III)
treatment induced PAI-1 protein expression under normoxia
by about 2-fold while it completely abrogated PAI-1 induction
under hypoxia resembling the effects observed for HIF-1α
under these conditions (Fig. 5a, b). Similar to PAI-1 and
HIF-1α protein levels, we found that HIF activity was upreg-
ulated by about 3-fold under hypoxia while As(III) increased
HIF activity by about 2.5-fold under normoxia and only by
about 2-fold under hypoxia (Fig. 5c).
Further, HO-1 levels increased by about 2.5-fold in re-
sponse to hypoxia, and by about 3.5 fold in response to
As(III) under normoxia. Interestingly, the As(III) treatment
under hypoxia increased HO-1 levels by 2.5-fold, similar to
the situation with hypoxia alone (Fig. 5a, b). Thus, PAI-1
regulation followed the HIF-1α regulation in response to
As(III) under normoxia and hypoxia, whereas the response
of HO-1 towards As(III) in particular under hypoxia did not
entirely parallel the response to HIF-1α suggesting an addi-
tional regulatory component.
Fig 2 As(III) induces HIF-1α at the transcriptional level. Cells were
cultured under normoxia for 24 h. After 24 h, the medium was changed
and cells were further cultured under normoxia and hypoxia in the
absence or presence of 50 μM As(III). a, b The HIF-1α mRNA
expression levels under normoxia (16 % O2) were set to 1. Values
represent means ± SEM of three independent experiments. Single
number sign, significant difference As(III) vs. respective control;
double asterisks, significant difference As(III) at 16 % O2 vs.
As(III) at 5 % O2; p ≤ 0.05. b Representative Northern blot. Twenty
micrograms of total RNA from cultured HepG2 cells were subjected to
Northern blot analysis and hybridized with DIG-labeled HIF-1α and β-
actin probes. Autoradiographic signals were visualized by
chemiluminescence and quantified by video densitometry
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Since HO-1 is also a bona fide target gene of the transcrip-
tion factor Nrf2 (nuclear factor (erythroid-derived 2)-like 2)
and well known to be responsive to As(III) [26], we also
examined the response of Nrf2 towards hypoxia and As(III).
Similar to HIF-1α, Nrf2 is regulated at the level of protein
stability. In order to assess whether hypoxia and As(III) affect
Nrf2 protein stability, we measured its half-life. In line with
previous reports, we found that cellular Nrf2 is maintained at
very low levels and that its half-life was about 15 min under
both normoxia and hypoxia. Treatment of cells with As(III)
extended the half-life of Nrf2 up to 30 min under normoxia
and hypoxia (Fig. 4d–f).
Next we investigated whether hypoxia and As(III) influ-
ence Nrf2 activity. To do this, cells were transfected with a
luciferase (Luc) reporter gene driven by Nrf2 binding antiox-
idant response elements (ARE) from the HO-1 gene in front of
a minimal promoter (p44-HO-1Luc). In line with the protein
half-life measurements, we found that hypoxia alone did not
significantly affect Nrf2 activity. However, As(III) induced
Nrf2 activity by about 8-fold under normoxia but only to
about 5-fold under hypoxia (Fig. 5c). Together, these data
suggest that Nrf2 could be involved in the As(III)-dependent
regulation of HO-1 and likely HIF-1α.
We next asked whether a cross-talk between HIF-1α and
Nrf2 exists. To test the possibility that Nrf2 could regulate
HIF-1α expression, we used cells in which Nrf2 was depleted
due to shRNA-mediated knockdown (Nrf2KD cells) and
treated them with As(III) under normoxia and hypoxia.
Similar to Nrf2 transcriptional activity, hypoxia had no effect
on Nrf2 levels but As(III) strongly induced Nrf2 abundance
under normoxia and hypoxia while these effects were greatly
diminished in Nrf2KD cells (Fig. 5d, e).
Hypoxia and treatment with As(III) under normoxia in-
duced HIF-1α by about 3-fold in the scrambled shRNA ex-
pressing control cells (Fig. 5d, e) as expected. Similarly, hyp-
oxia induced HIF-1α levels also in Nrf2-depleted cells.
Fig. 3 Induction of HIF-1α by As(III) is dependent on mTORC1-driven
protein synthesis. Cells were cultured under normoxia for 24 h. At 24 h,
the medium was changed and the cells were pre-treated for 30 min either
with cycloheximide (CHX, 10 μg/ml) (a, b) or rapamycin (10 μM) (c, d)
and then treated with 50 μM As(III) under normoxia (16 % O2) or
hypoxia (5 % O2) for 4 h. a, c Statistical analyses of HIF-1α levels.
The HIF-1α levels in the controls were set to 1. Values represent mean
± SEM of three independent experiments. Single asterisk, significant
difference 16 % O2 vs. 5 % O2; single number sign, significant
difference As(III) vs. control; double asterisks, significant difference
16 % O2 +As(III) vs. rapamycin at 16 % O2 +As(III); double number
sign, significant difference rapamycin at 5 % O2 vs. rapamycin at 5 %
O2 +As(III); single plus sign, significant difference As(III) 16 % O2 vs.
As(III)/CHX16%O2; double plus sign, significant difference As(III) 5%
O2 vs. As(III)/CHX 5 % O2; p ≤ 0.05. b, d Representative Western blot.
One hundred micrograms of isolated total protein was subjected to
Western blot analysis with an antibody against HIF-1α, Golgi
membrane (GM), phospho-p70S6K1, or total p70S6K1. Signals were
visualized by chemiluminescence and quantified by video densitometry
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However, As(III) was not able to induce HIF-1α, neither un-
der normoxia nor under hypoxia (Fig. 5d, e). Concomitantly,
PAI-1 and HO-1 expression showed the same pattern
(Fig. 5e). Together, these data show that Nrf2 contributes to
the As(III)-dependent regulation of HIF-1α levels.
Role of ROS in As(III)-induced HIF-1α levels
The surprising involvement of the redox-sensitive transcription
factor Nrf2 in the As(III)-dependent induction of HIF-1α raised
the question whether alterations in the levels of ROS contribute
to the As(III)-dependent HIF-1α induction. Indeed, As(III)-
treated cells displayed an enhanced ROS formation (Fig. 6a).
NADPH oxidases (NOX) have a fundamental role in
ROS generation, and in particular, NOX4 appears to be
involved in st imulus-dependent ROS format ion.
Therefore, we investigated the possible involvement of
NOX4 in the induction of ROS and the HIF-1α response
to As(III). To do this, we used cells in which we depleted
NOX4 by specific shRNA. The results demonstrate that
NOX4 is involved in the induction of ROS in response to
As(III) (Fig. 6a). In addition, and as shown earlier [27, 28],
we found that NOX4 is induced by hypoxia. However,
treatment of cells with As(III) induced NOX4 only under
normoxia (Fig. 6c, d). In line, NOX4 depletion reduced
HIF-1α induction in response to As(III). As expected and
in agreement with earlier data [23], NOX4 depletion also
reduced hypoxia-dependent HIF-1α induction while it did
not affect HIF-1α levels under combined treatment
(Fig. 6b, c). In order to address whether the NOX4 effects
on HIF-1α are mediated at least in part by Nrf2, we exam-
ined Nrf2 activity along with HIF-1 activity upon depletion
of NOX4. We found that knockdown of NOX4 reduced
induction of HIF-1α activity by As(III) and hypoxia
(Fig. 6d). Interestingly, depletion of NOX4 was without
effect on the Nrf2 activity under hypoxia while it reduced
the As(III)-mediated Nrf2 activity under normoxia to about
the same levels as observed under hypoxia (Fig. 6d).
Together, these data indicate that NOX4 is involved in the
Fig. 4 Modulation of HIF-1α and Nrf2 half-life by As(III). HepG2 cells
were cultured under normoxia for 24 h. At 24 h, the mediumwas changed
and the cells were treated with 50 μMAs(III) under normoxia (16 % O2)
or hypoxia (5 % O2) for 4 h. After 4 h, cells were treated with
cycloheximide (CHX, 10 μg/ml) for the indicated times. a The HIF-1α
levels in the As(III)-treated controls were set to 1. Values represent mean
± SEM of three independent experiments. b, c Representative Western
Blots. One hundred micrograms of isolated total protein was subjected
to Western blot analysis with an antibody against HIF-1α or α-tubulin. d
The Nrf2 levels in the As(III)-treated controls were set to 1. Values
represent mean ± SEM of three independent experiments. e, f
Representative Western Blots. One hundred micrograms of isolated
total protein was subjected to Western blot analysis with an antibody
against Nrf2 or α-tubulin
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As(III)-dependent regulation of HIF-1α by regulating Nrf2
activity.
It is well known that the ERK1/2 MAPK pathway and the
PI3K/Akt pathway are major downstream mediators in the
NOX signal chain in response to non-hypoxic stimuli [29].
Since As(III) appeared to act via NOX4, we further investi-
gated whether the ERK1/2 and the PI3K/Akt pathways which
are able to also activate Nrf2 [30] participate in the transduc-
tion of the As(III) effects.We found that As(III) treatment lead
to phosphorylation of ERK1/2, and Akt; however, only deple-
tion of NOX4 but not of NOX1 abolished ERK1/2 and Akt
phosphorylation (Fig. 6e). No effects were noted under hyp-
oxia (data not shown). In addition, we used specific inhibitors
of the PI3K/Akt pathway and the ERK1/2 pathway and found
that the PI3K inhibitor LY294002 abolished not only phos-
phorylation of Akt but also that of ERK1/2. By contrast, the
MEK inhibitor U0126 only abolished the As(III)-dependent
activation of ERK1/2 suggesting that phosphorylation of Akt
is the upstream event necessary for the activation of ERK1/2
in response to As(III). In line, both inhibitors reduced the
As(III)-induced increase in Nrf2 (Fig. 6f). Together, these data
indicate that As(III) contributes to the regulation of HIF-1α
via activation of NOX4, the PI3K/Akt and ERK1/2 pathway,
and Nrf2.
As(III) induces proliferation, angiogenesis, and colony
formation via HIF-1α and Nrf2
We next determined whether the As(III)/Nrf2-mediated HIF-
1α regulation is involved in cell proliferation. To test this, we
used cells in which Nrf2 or HIF-1α were knocked-down and
measured the impact of As(III) on BrdU incorporation into
newly synthesized DNA. We found that under normoxia,
As(III) increased cell proliferation by about 30% in scrambled
shRNA transfected control cells while Nrf2 or HIF-1α knock-
down abolished the As(III) effect (Fig. 7a, b). By contrast,
As(III) decreased cell proliferation under hypoxic conditions
Fig. 5 As(III) affects HIF-target gene expression and knockdown of
Nrf2 abolishes As(III)-dependent HIF-1α induction. HepG2 cells were
cultured under normoxia for 24 h. At 24 h, the cells were treated with
50 μM As(III) and further cultured for the next 12 h under normoxia
(16 % O2) or hypoxia (5 % O2). a Statistical analyses of the PAI-1 and
HO-1 protein levels. The PAI-1 and HO-1 levels under normoxia were set
to 1. Values are means ± SEM of at least four independent experiments.
Single asterisk, significant difference 16 % O2 vs. 5 % O2; single number
sign, significant difference As(III) vs. control; p ≤ 0.05. b Representative
Western Blot. One hundred micrograms of protein from the cell culture
medium or total protein lysates was analyzed by Western blot analysis
with an antibody against PAI-1, HO-1, and Golgi membrane (GM). c
Cells were transfected with Luc gene constructs containing either three
copies of the hypoxia-inducible factor (HIF) binding HRE element
(pHRE-Luc) or the Nrf2 binding antioxidant response element (ARE)
from the HO-1 gene in front of a minimal promoter (p44-HO-1Luc).
The transfected cells were treated with 50 μM As(III) and further
cultured for 24 h under normoxia or hypoxia. In each experiment, the
LUC activity of the respective control at 16 % O2 was set to 1. Values are
means ± SEM of three independent culture experiments; single asterisk,
significant difference 16%O2 vs. 5 %O2; single number sign, significant
difference As(III) vs. control. d Statistical analyses of the HIF-1α and
Nrf2 protein levels. Cells were cultured under normoxia for 24 h. At 24 h,
the cells were treated with 50 μMAs(III) and further cultured for the next
8 h under normoxia (16 % O2) or hypoxia (5 % O2). The expression of
HIF-1α under normoxia was set to 1. Values are means ± SEM of at least
four independent experiments. Single asterisk, significant difference
control 16 % O2 vs. 5 % O2; single number sign, significant difference
As(III) vs. control. e Representative Western Blots. One hundred
micrograms of total protein was analyzed by Western blot with an
antibody against HIF-1α, Nrf2, PAI-1, HO-1, and α-tubulin
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and knocking down HIF-1α or Nrf2 augmented these effects
(Fig. 7a, b).
Since HIF-1α and Nrf2 are associated with the regulation
of angiogenesis and tumor cell colony formation [31], we next
tested whether As(III) affects capillary formation in endothe-
lial cells and tumor colony growth of hepatoma cells in a HIF-
1α or Nrf2-dependent manner using an in vitro matrigel assay
and colony formation assay. Interestingly, As(III) induced
both the formation of capillary-like structures and colonies
under normoxic conditions. Knockdown of either Nrf2 or
HIF-1α decreased formation of capillary-like structures as
well as tumor cell colonies. By contrast, when capillary- and
colony formation was assessed under hypoxia, it was found
that As(III) reduced the hypoxia-dependent generation of
capillary-like structures and colonies (Fig. 7c–f). Together,
these data indicate that the regulation of HIF-1α and Nrf2
by As(III) contributes to the angiogenic responses of endothe-
lial cells and the colony-forming properties of hepatoma cells.
Fig. 6 Involvement of ROS, NOX4, PI3K, and ERK1/2 in the response
to As(III). Cells transfected with scrambled shRNA (shScr) or shRNAs
against NOX4 (shNOX4) were cultured under normoxia for 24 h. At
24 h, the medium was changed and the cells were treated with 50 μM
As(III) for 15 min under normoxia (16 % O2) or hypoxia (5 % O2). ROS
formation was measured with the DCFH assay. a Statistical analyses of
ROS formation. Values represent mean ± SEM of at least three
independent experiments. Single asterisk, significant difference shScr
vs. shNOX4; double asterisks, significant difference shScr vs. shScr +
As(III) or shScr + As(III) vs. shNOX4 + As(III). b Cells transfected
as above were treated with 50 μM As(III) and further cultured for 4 h
under normoxia (16 % O2) or hypoxia (5 % O2). The HIF-1α protein
levels in the controls under normoxia were set to 1. Values represent
mean ± SEM of at least three independent experiments. Single asterisk,
significant difference 16%O2 vs. 5 %O2; double asterisks, shScr 5%O2
vs. shNOX4 5 %O2; double number sign, shScr + As(III) vs. shNOX4 +
As(III). c RepresentativeWestern blots. One hundred micrograms of total
protein was subjected to Western blot analysis with an antibody against
HIF-1α, NOX4, or Golgi membrane (GM). d Cells were transfected with
scrambled shRNA (shScr) or shRNAs against NOX4 (shNOX4) and Luc
gene constructs containing either three copies of the hypoxia-inducible
factor (HIF) binding HRE element (pHRE-Luc) or the Nrf2 binding
antioxidant response element (ARE) from the HO-1 gene in front of a
minimal promoter (p44-HO-1Luc). The transfected cells were treated
with 50 μM As(III) and further cultured for 24 h under normoxia or
hypoxia. In each experiment, the LUC activity of the respective control
at 16 % O2 was set to 1. Values are means ± SEM of three independent
culture experiments; single asterisk, significant difference 16 % O2 vs.
5 % O2; double asterisks, shScr 5 % O2 vs. shNOX4 5 % O2; single
number sign, shScr vs. shScr + As(III) or shNOX4 + As(III). e Cells
transfected with scrambled shRNA (shScr) or shRNAs against NOX4
(shNOX4) were cultured under normoxia for 24 h. At 24 h, the medium
was changed and the cells were treated with 50 μM As(III) for 15 min.
Thereafter proteins were harvested and subjected toWestern analysis with
antibodies against phospho-ERK1/2, phospho-Akt, NOX1, NOX4, and
Golgi membrane (GM). f Cells were cultured as in e; but after 24 h, they
were pre-treated for 30 min with 20 μM of the PI3K inhibitor LY294002
or the MEK inhibitor U0126, before treatment with 50 μM As(III).
Proteins were harvested after 15 min for the respective blots. One
hundred micrograms of total protein was subjected to Western blot
analysis with antibodies against phospho-ERK1/2, phospho-Akt, Nrf2,
and Golgi membrane (GM)
J Mol Med (2016) 94:1153–1166 1161
Discussion
In this study, we identified a novel mechanism by which As(III)
can induce HIF-1α and contribute to proliferation and angiogen-
esis. Thereby,As(III) exerts effects onHIF-1α viaNrf2-mediated
enhancement of transcription which is connected to ROS gener-
ation involving NOX4, stimulation of the PI3/Akt and ERK1/2
pathways as well as by increasing the HIF-1α half-life.
Although previous reports showed that As(III) can act as
inducer of HIF-1α [20, 32], those studies were only focusing
on partial aspects of the participating signal chains. Our study
confirms several mechanistic aspects but is the first identify-
ing two novel participating entities, namely the NADPH oxi-
dase NOX4 and the transcription factor Nrf2.
The generation of ROS in response to As(III) was already
described earlier [33] and the current study confirmed this in
the hepatoma cell line HepG2. However, this phenomenon is
not restricted to hepatocyte-derived cells as in this study but
was also reported to occur in various other cell types [34–36].
Furthermore, earlier findings suggested that a thiol-sensitive
mechanism contributes to the As(III)-inducedVEGF andHIF-
1α expression in human ovarian cancer cells [18].
In line with these findings and the knowledge that HIF-1α
can be regulated by ROS (reviewed in [37–39]), it was tempt-
ing to investigate whether the ROS were generated due to the
action of NADPH oxidases. Earlier reports have given hints
that NOX proteins contribute to arsenite-induced ROS pro-
duction [40–43]. However, due to the use of non-selective
Fig. 7 Influence of As(III) on cell proliferation. a HepG2 cells were
cultured in 96-well plates under normoxia for 24 h. At 24 h, the
medium was changed and the cells were transfected with plasmids
expressing control scrambled shRNA (shCtr) or shRNA against HIF-
1α or Nrf2. The next day, cells were cultured in the absence or
presence of As(III) under normoxia (16 % O2) or hypoxia (5 % O2).
After 4 h, BrdU assay was performed. Values represent mean ± SEM of
at least three independent experiments. Single asterisk, significant
difference control vs. As(III). Double asterisks, significant difference
As(III) vs. As(III) + shNrf2 or As(III) + shHIF-1α. b Representative
Western Blot. One hundred micrograms of total protein was subjected
to Western blot analysis and probed with an antibody against HIF-1α,
HO-1, or Golgi membrane (GM). c HMEC-1 cells were transfected with
vectors for control scrambled shRNA (shScr) or shRNA against HIF-1α
or Nrf2. Cells were plated onto matrigel-coated wells for 2 h and then
exposed to As(III) under normoxia or hypoxia for 4 h. The number of
tubules from each well was counted using ImageJ software. Data
represent the number of tubules relative to the control which was set to
100 %. Single asterisk, significant difference shScr vs. As(III) + shScr.
Double asterisks, significant difference As(III) + shScr vs. As(III) +
shNrf2 or As(III) + shHIF-1α. d Photographs from a representative
in vitro angiogenesis experiment. e Hep3B liver carcinoma cells were
transfected as above. Cells were seeded onto six-well plates, exposed to
As(III), and grown for 4 days. Data are presented as sum of colony
volume (Σ(V)) and sum of area (Σ(A)), respectively, relative to the
control which was set to 100 %. Single asterisk, significant difference
shScr vs. As(III) + shScr. Double asterisks, significant difference
As(III) + shScr vs. As(III) + shNrf2 or As(III) + shHIF-1α. f
Photographs from a representative colony formation assay
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inhibitors like diphenyleneiodonium chloride (DPI) [44], it
was so far not possible to identify the proper participating
NOX member. The present study closes this gap; by using a
specific knockdown approach, we were able to show that
NOX4 is the predominant enzyme participating in As(III)-
dependent ROS generation and HIF-1α induction. Our earlier
findings [45, 46] and reports from other groups on ROS-
dependent HIF-1α regulation [47–49] showed that the PI3K/
Akt and the ERK1/2 MAPK pathways are of importance.
Accordingly, we examined the involvement of both pathways
and found that NOX4 acts upstream of the PI3K/Akt pathway
and the ERK1/2 pathway, respectively. The latter findings are
to some extent in line with earlier data reporting that activation
of the Akt pathway contributes to the As(III)-increased HIF-
1α level [20, 50, 51], though there was also a report which
challenged the participation of the Akt pathway [44].
Although activation of ERK1/2 signaling was reported earlier
to participate in the As(III)-mediated expression of
angiogenesis-related factors and induction of HIF-1α [52,
53], our study is now first to show that the PI3K/Akt pathway
and ERK1/2 pathways are interlinked and that the PI3K/Akt
pathway acts upstream of ERK1/2.
In addition, we show for the first time that As(III) induced
upregulation of HIF-1α mRNA under normoxia. The usage of
cells with knockdown for the redox-sensitive transcription factor
Nrf2 indicated that this factor plays a crucial role in the As(III)-
dependent HIF-1α transcriptional regulation. Moreover, we
showed that both Nrf2 and HIF-1α are participating in the
As(III)-driven proliferation and angiogenic response. Indeed,
similar links between HIF-1α and Nrf2 already appear to exist.
For example, Nrf2 blockade seems to be of primary importance
for tumors of the digestive tract. In particular, Nrf2 blockade
suppressed colon tumor angiogenesis by inhibiting HIF-1α
[54] and migration and invasion of esophageal squamous cell
carcinoma cells in a hypoxic microenvironment [55]. In liver, it
was found that Nrf2 contributes to ischemia-induced hepatocel-
lular damage [56]. However, the action of the Nrf2 connection is
not restricted to the digestive tract since knockdown of Nrf2 in
glioma cells suppressed glioblastoma angiogenesis in vitro and in
xenotransplanted mice by inhibiting HIF-1α [31, 57].
Vice versa, Nrf2 activation improved cell survival during
hypoxia and hypoxia/reoxygenation in cardiomyoblasts [58],
although in this study Nrf2 protein and activity were not in-
duced by hypoxia.
Further, and in line with our study, the link between Nrf2
and NOX4 was also evident in cardiomyocytes [59].
However, the participation of NOX4 in the As(III) effects does
not preclude that other NOX isoforms may also regulate the
Nrf2-HIF-1α system. It is possible that, dependent on the cell-
specific expression of the NOX proteins (for review, see [37]),
other NOX isoforms may have similar effects. In that respect,
an earlier study was able to show that the induction of the Nrf2
pathway in NOX1-expressing adenocarcinoma A549 cells
augments HIF-1α signaling [60]. By contrast, also a feedback
loop in which HIF-1 induction attenuates Nrf2-dependent
gene expression appears to exist [61] indicating the complex-
ity of the regulatory mechanism.
The connection between ROS, hypoxia, NOX4, Nrf2, and
HIF-1α seems to play an important role in fibrosis where
hypoxia is a major sign due to loss of endothelial cells,
rarefication of capillaries, and malperfusion. In line with that,
it was found that NOX4-deficient mice exhibited attenuated
angiogenesis [62] and targeting NOX4-Nrf2 could reverse
persistent fibrosis in lungs of aging mice [63].
In addition to the transcriptional induction by As(III) under
normoxia, we could also detect that As(III) downregulated the
HIF-1α mRNA levels under hypoxia which subsequently ex-
plains the decreased HIF-1α protein levels in hypoxic As(III)-
treated cells. This decrease is due to the lower activity of Nrf2
under hypoxia upon As(III) treatment and although the cells
tried to counteract this decreased transcription by an increase
in HIF-1α protein stability, a full compensation could not be
reached. The stabilization of HIF-1α in response to As(III) is
primarily achieved due to the action of ROS which inhibit the
action of proline hydroxylases [23, 24] and similar findings
were reported by another study showing that As(III) inhibits
HIF-1α degradation via ROS at the level of proline hydrox-
ylation [44]. In view of these findings, the current data support
a model where, under normoxia, As(III) induces HIF-1α
mRNA transcription, HIF-1α protein synthesis, HIF-1α target
gene expression as well as cell proliferation and angiogenesis
via NOX4 and the redox-sensitive transcription factor Nrf2 in
conjunction with activation of PI3K/Akt and ERK1/2. Under
hypoxia, As(III) does not induce NOX4 so that less ROS are
formed with the consequence that HIF-1α can no longer be
efficiently transcribed due to diminished Nrf2 activity. To
overcome this deficit, cells prolong the half-life of HIF-1α;
however, the transcriptional reduction appears to be only par-
tially compensated with the net result that the overall HIF-1α
protein levels are reduced with the consequence that cell pro-
liferation and angiogenesis are strongly impaired. Overall, the
current study is the first where As(III)-dependent effects were
examined under normoxia and hypoxia and where different
modes of HIF-1α transcription via Nrf2 have been identified
(Fig. 8).
Although our findings with HepG2, Hep3B, and
HMEC1 cells support the tumor growth-promoting role of
As(III), additional studies will be required to determine
whether other cancer cell types respond similarly to
As(III) treatment. These findings can then also be seen in
the context of therapeutical use. Since HIF-1α and tumor
hypoxia are considered to be associated with tumor pro-
gression [64], it would be beneficial to downregulate HIF-
1α under hypoxic conditions as seen in the current study.
Indeed, these findings may help to explain why arsenic is of
therapeutical use; it gained a renaissance based on recent
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reports from China describing that a traditional Chinese
medicine, BAi-ling 1,^ in which arsenic is the active ingre-
dient, can be used to successfully treat patients with acute
promyelocytic leukemia (APL) [65–67]. A number of clin-
ical trials using arsenic to treat patients with APL confirmed
the beneficiary effects [68, 69] with the consequence that
arsenic has been approved as a standard therapy for the
treatment of patients with relapsed or refractory APL in
the USA and Europe [70] EU/1/02/204/001; http://ec.
europa.eu/enterprise/pharmaceuticals/orphanmp/index.
htm.
Overall, these findings and the results of the present study
indicate that As(III) has an ambivalent mode of action with
having profound effects on cell growth and angiogenesis
which are associated with diseases like cancer as well as hav-
ing use as therapeutic agent. The current study adds new
knowledge to better understand the pro-carcinogenic mecha-
nisms of As(III), and at the same time it aims to further foster
the discussion and research to unravel the mechanisms behind
the anti-carcinogenic actions of As(III).
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